Summary & Overview
HCPCS Level II J1300: Injection, eculizumab, 10 mg
HCPCS Level II code J1300 designates the drug product entry for eculizumab billed in 10 mg units. Eculizumab is a high-cost monoclonal antibody used for rare, serious conditions and its billing is closely monitored across payers because of clinical complexity and budgetary impact. Nationally, clarity about drug-unit coding and site-of-service affects coverage determinations, utilization management, and reimbursement workflows.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J1300 represents, typical sites of service for administration, and the common payer landscape. The publication summarizes available benchmarks for utilization and reimbursement patterns where available, highlights policy considerations that affect prior authorization and coverage, and provides clinical context for eculizumab administration.
This summary is intended for billing managers, pharmacy and therapeutics staff, hospital revenue cycle teams, and policy analysts seeking clear, national-level information about coding, clinical setting, and payer considerations for HCPCS Level II code J1300. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1300 represents a medication administration entry for eculizumab, billed per 10 mg of the drug. The service type is drug injection/infusion. The typical site of service for this code is an outpatient infusion center, hospital outpatient department, or physician office where parenteral biologic therapies are administered.
Clinical & Coding Specifications
Clinical Context
A 28-year-old patient with paroxysmal nocturnal hemoglobinuria (PNH) presents to an outpatient infusion center for maintenance therapy with eculizumab. The patient has prior authorization and baseline meningococcal vaccination documented. Nursing performs pre-infusion vital signs, reviews concurrent medications, and confirms no active infection. Pharmacy verifies dose based on weight and prepares J1300 (injection, eculizumab, 10 mg) in a sterile syringe. The infusion nurse administers the medication intravenously per institutional protocol, monitors for infusion reactions for at least 60 minutes, documents lot number and expiration, and records the number of vials billed using J1300 units. Billing captures the diagnosis code(s) supporting medical necessity, the appropriate HCPCS units, and any applicable modifiers for payer adjudication. Typical site of service is an outpatient infusion center or hospital outpatient department; occasional administration occurs in physician office infusion suites for eligible patients.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Anticipated / actual performance of the service by the billing provider | Use when the ordering and billing clinician also performs the infusion-related service component eligible for Modifier per payer rules |